Thursday, June 2, 2016: 6:15 PM-8:15 PM
Exhibit Hall
Dutch Guideline Adherence First-Line Injection Therapy Multiple Sclerosis
Astrid Slettenaar, MANP, MS-center Twente;
Monique Booy, MANP, Amphia Hospital, MS centre;
Lisette Trommelen, MANP, MS-center Midden Brabant;
Tiny Kempkens, MANP, Zuyderland ziekenhuis;
Kitty Harrison, MANP, Tergooi Ziekenhuis;
Klaas Arts, MD, neurologist, Winkler clinic, Pro Persona;
Annette Baars, Master neurorevalidatie en innovatie, Rijnstate ziekenhuis;
Leo Visser, Professor, PhD, MD, neurologist, MS-center Midden Brabant
A Multicenter Randomized Controlled Trial Comparing Immediate and 6-Month Follow-up Effects of Two Group Programs on Fatigue and Self-Efficacy in People with MS
Cinda L Hugos, MS, PT, VA Portland Health Care System;
Yiyi Chen, PhD, Oregon Health & Science University;
Zunqiu Chen, MS, Oregon Health & Science University;
Aaron P Turner, Ph.D. ABPP (RP), VA Puget Sound Health Care System;
Jodie K Haselkorn, MD, MPH, VA Puget Sound Health Care System;
Toni Chiara, PhD, PT, Malcom Randall VA Medical Center;
Sean McCoy, PhD, Malcom Randall VA Medical Center;
Christopher Bever Jr., MD, MBA, FAAN, VA Maryland Healthcare System;
Dennis Bourdette, MD, VA Portland Health Care System;
Cinda L Hugos, MS, PT, VA Portland Health Care System
The Meaning of Physical Activity, Exercise and Sedentary Behavior in Persons with Multiple Sclerosis
Dominique L Kinnett-Hopkins, BS, University of Illinois at Urbana Champaign;
Robert W Motl, PhD, University of Illinois at Urbana-Champaign;
Elizabeth A Hubbard, MSc, University of Illinois at Urbana-Champaign;
Edward McAuley, PhD, University of Illinois at Urbana Champaign;
Lara A Pilutti, PhD, University of Illinois at Urbana-Champaign;
Yvonne C Learmonth, PhD, University of Illinois at Urbana-Champaign;
Dominique L Kinnett-Hopkins, BS, University of Illinois at Urbana Champaign
Real-World Comparison of Adherence and Persistence Among African-Americans with Multiple Sclerosis Treated with Fingolimod Versus Glatiramer Acetate
Mitzi J. Williams, MD, Multiple Sclerosis Center of Atlanta;
Yujin Park, PharmD, University of Maryland School of Pharmacy;
Kristen Johnson, PhD, MPH, Novartis Pharmaceuticals Corporation;
Rachel Halpern, PhD, MPH, Optum;
Helen Trenz, MA, Optum;
Stephanie Korrer, MPH, Optum;
Vivian Herrera, DDS, MIA, MPH, Novartis Pharmaceuticals Corporation;
Rachel Halpern, PhD, MPH, Optum;
Kristen Johnson, PhD, MPH, Novartis Pharmaceuticals Corporation
Real-World Comparison of Adherence and Persistence Between Hispanic Patients with Multiple Sclerosis Initiating Fingolimod or Glatiramer Acetate
Mitzi J. Williams, MD, Multiple Sclerosis Center of Atlanta;
Yujin Park, PharmD, University of Maryland School of Pharmacy;
Kristen Johnson, PhD, MPH, Novartis Pharmaceuticals Corporation;
Rachel Halpern, PhD, MPH, Optum;
Helen Trenz, MA, Optum;
Stephanie Korrer, MPH, Optum;
Vivian Herrera, DDS, MIA, MPH, Novartis Pharmaceuticals Corporation;
Rachel Halpern, PhD, MPH, Optum;
Kristen Johnson, PhD, MPH, Novartis Pharmaceuticals Corporation
Relapse Management in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from a Real-World Analysis of Treatment Patterns
Robert J Fox, MD, FAAN, Cleveland Clinic;
David Templeton, MBA, Medical Data Analytics;
Beth Lesher, PharmD, BCPS, Pharmerit International;
Manoj Malhotra, MD, Mallinckrodt Pharmaceuticals;
Beth Lesher, PharmD, BCPS, Pharmerit International
Low Risk of New Flu-like Symptoms in Patients Transitioning from Non-Pegylated to Pegylated Interferon Beta-1a and Mitigation with Scheduled Naproxen
Robert T Naismith, MD, Washington University School of Medicine;
Barry Hendin, M.D., Phoenix Neurological Associates;
Sibyl Wray, MD, Hope Neurology Multiple Sclerosis Center;
DeRen Huang, MD, PhD, Neurology and Neuroscience Associates;
Phil You, PhD, Biogen;
Brian Werneburg, PhD, Biogen;
Nick White, B.A., CircleScience USA
